Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - clopidogrel hydrogen sulfate, quantity: 97.9 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; lactose; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; sodium lauryl sulfate; titanium dioxide; hypromellose; macrogol 8000; polydextrose; macrogol 400 - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. acute coronary syndrome: piax is indicated in combination with aspirin for patients with:- unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). piax is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). -st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, piax has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - clopidogrel hydrogen sulfate, quantity: 97.9 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: lactose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; sodium lauryl sulfate; macrogol 8000; hypromellose; macrogol 400; titanium dioxide; polydextrose - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. acute coronary syndrome: piax is indicated in combination with aspirin for patients with:- unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). piax is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). -st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, piax has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - clopidogrel besilate, quantity: 111.86 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: mannitol; microcrystalline cellulose; colloidal anhydrous silica; stearic acid; hypromellose; titanium dioxide; iron oxide red - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.,acute coronary syndrome,clopidogrel is indicated in combination with aspirin for patients with,-unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-termatherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent).,- st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in thispopulation, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hyprolose; hydrogenated vegetable oil; mannitol; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide red; macrogol 400; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; iron oxide black; shellac; sulfuric acid; ammonia; strong ammonia solution; ethanol - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride, quantity: 22.2 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate; lactose; hyprolose; hypromellose; macrogol 8000; titanium dioxide - treatment of major depression and prevention of relapse of depressive symptoms. treatment of obsessive compulsive disorder (ocd) and prevention of relapse of ocd. treatment of panic disorder and prevention of relapse of panic disorder. treatment of social anxiety disorder / social phobia. treatment of generalised anxiety disorder. treatment of post-traumatic stress disorder.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; carnauba wax; mannitol; macrogol 6000; hyprolose; hydrogenated castor oil; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. acute coronary syndrome: clopidogrel winthrop is indicated in combination with aspirin for patients with: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel winthrop is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent); st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel winthrop has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - doxylamine succinate, quantity: 5.1 mg; codeine phosphate hemihydrate, quantity: 10 mg; paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: maize starch; povidone; purified talc; magnesium stearate; pregelatinised maize starch; sodium lauryl sulfate; colloidal anhydrous silica; hyprolose; stearic acid - for the temporary relief of acute moderate pain

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - codeine phosphate hemihydrate, quantity: 30 mg; paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: povidone; pregelatinised maize starch; croscarmellose sodium; maize starch; potassium sorbate; microcrystalline cellulose; stearic acid; magnesium stearate; purified talc - comfarol forte is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - bromhexine hydrochloride, quantity: 8 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch - for use as a mucolytic to break down mucus and help clear the chest in conditions accompanied by excessive mucus secretions such as in the common cold, influenza, infections of the respiratory tract or in other conditions where excess mucus is produced.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - carvedilol, quantity: 12.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; crospovidone; microcrystalline cellulose; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - dicarz is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. dicarz is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii -iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).